Novamind to Present at Life Sciences Investor Forum
Novamind Inc. (CSE:NM)(OTCQB:NVMDF) announced its participation in the Life Sciences Investor Forum on September 16, 2021, at 12:00 PM EST. Dr. Reid Robison, the Chief Medical Officer, will present Novamind's plan for expanding access to psychedelic medicine across the U.S. through its clinics and research sites. An open Q&A session will follow the presentation, and a recorded webcast will be available for those unable to attend live. Novamind focuses on mental health with services such as ketamine-assisted psychotherapy.
- None.
- None.
TORONTO, ON / ACCESSWIRE / September 14, 2021 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, is pleased to announce its participation in the Life Sciences Investor Forum, taking place virtually on Thursday, September 16 at 12:00 PM EST.
Join Novamind's Chief Medical Officer and Director, Dr. Reid Robison, live as he presents the Company's model for scaling access to psychedelic medicine through a multi-state, U.S. expansion of leading psychiatry clinics and clinical research sites. Investors are invited to participate in an open Q&A session following the presentation.
An archived webcast will be made available for attendees who are not able to join the event live.
Click here to join the webcast.
About Novamind
Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics and clinical research sites. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of Cedar Psychiatry clinics and operates Cedar Clinical Research, a contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. Both Cedar Psychiatry and Cedar Clinical Research are wholly owned subsidiaries of Novamind. For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visit novamind.ca.
Contact Information
Novamind
Yaron Conforti, CEO and Director
Telephone: +1 (647) 953 9512
Samantha DeLenardo, VP, Communications
Email: media@novamind.ca
Bill Mitoulas, Investor Relations
Email: bill@novamind.ca
Forward-Looking Statements
This news release contains forward-looking statements. All statements other than statements of historical fact included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations including the risks detailed from time to time in the Company's public disclosure. The reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable laws.
SOURCE: Novamind Inc.
View source version on accesswire.com:
https://www.accesswire.com/663859/Novamind-to-Present-at-Life-Sciences-Investor-Forum
FAQ
What is Novamind's participation in the Life Sciences Investor Forum?
Who is presenting for Novamind at the investor forum?
When is the Life Sciences Investor Forum taking place?
Will there be a Q&A session during Novamind's presentation at the forum?
Is there a way to access Novamind's presentation if I can't attend live?
What is the focus of Novamind's services?
